BioTrinity, Europe’s leading life sciences biopartnering and investment conference London, 30 April and 1 May

**BioTrinity Overview**

Throughout BioTrinity, a series of targeted panel discussions will be delivered aiming to address, ‘What’s New’ in the most prominent therapy areas, including Oncology, Neurodegenerative Disease, Autoimmune Disease, Cell & Gene Therapy, Mental Health and Metabolic Diseases.

Our expert and balanced panels will consider recent innovations, investment trends, challenges and projected future developments in each space and will include representation from across the industry including Big Pharma, smaller R&D innovators, investors, clinicians, academics and charities.

The panel discussions feed into a broader theme of ‘Healthy Ageing’, that will be addressed via two keynote presentations on Day One and Day Two of the conference.

---

**Panel Abstracts and Speakers – Tuesday 30 April**

09.40 - 10.15

**Keynote: Healthy Ageing for the 21st century: Targets, Therapies and Timing**

Nishi Chaturvedi, Professor of Clinical Epidemiology (Cardiometabolic Disease), UCL

Professor Chaturvedi obtained her first degree in medicine at London University in 1985, and then went on to specialist training in general medicine, public health and epidemiology. Her post-doctoral positions were held at the Department of Epidemiology at UCL. Professor Chaturvedi was appointed to a chair of clinical epidemiology in the National Heart & Lung Institute at Imperial College London in 2000. She returned to a chair in clinical epidemiology in the Institute of Cardiovascular Sciences at UCL in 2014.
10.15 - 11.10

Panel: What’s New in Metabolic Diseases, kindly sponsored by Novo Nordisk

There are two main causes of Metabolic Diseases; either a rare inherited genetic disorder or via acquired environmental and lifestyle factors.

The former is relatively rare affecting in the region of 1 in 1,000 – 2,000 of the population and progress is being made on management of the conditions through diet and more recently, through strategies to replace enzymes that are deficient.

Acquired metabolic disorders are much more in the limelight with type 2 diabetes and its knock-on effects becoming a major burden on healthcare systems. Accumulating evidence suggests that although some people are more disposed to the clinical consequences of dysregulated glucose metabolism many cases can be avoided in the first place through altered behaviour.

Nevertheless, many millions of people (need to) receive treatment to achieve blood glucose control and many drugs are under development for control of satiety and to direct weight loss.

This session aims to give an update on recent progress in the development of drugs to address this multifaceted problem and also to address how non-pharmaceutical strategies can be blended with these to achieve control of this ‘epidemic’.

Areas to be covered by the panel include:
- What are the remaining challenges in metabolic diseases (which unmet needs remain?)
- What’s in the drug pipeline for cardio-metabolic diseases?
- Update on cell-based therapy approaches
- New frontiers in cardio-vascular protection
- The potential of using AI in the discovery of novel therapeutic targets within metabolic diseases
- Going from drugs to health solutions
- How to obtain value from digital health approaches that keep people healthy?

Chair: Bill Haynes, Head & Vice President, Novo Nordisk Research Centre, Oxford

Panellists:
1. Jacob Sten Petersen, Corporate Vice President, Stem Cell R&D, Novo Nordisk
2. Andrew Hopkins, CEO, Exscientia
3. Iain Wilcock, Investment Advisor, Seventure Partners
4. Jorge Ferrer, Chair in Genetics and Medicine, Imperial College London
5. Mike Trenell, Director, NIHR Innovation Observatory, Newcastle University
Panel: What’s New in Oncology, kindly sponsored by Precision for Medicine, Oncology and Rare Disease

In recent years there have been major developments in both the prevention of cancer and the survival rates of cancer patients, however cancer remains a leading cause of death in Europe and the US. Our panel of opinion leaders from across the industry will consider recent developments across a range of topics, including:

- Successes for new therapies and new therapeutic strategies, over the last year
- The roll out of CAR-T therapies; where are we now and what progress can be expected
- The barriers to CAR-T therapy adoption - what are the potential solutions and limitations of the technology?
- What are the next generation therapies?
- What progress has been made in treating solid tumors and hard to treat cancers, such as pancreatic cancer?
- The progress and prospects for cancer vaccines
- The business strategies making cutting edge treatments available to patients
- Conventional approaches to treat cancer vs life style approaches to reduce cancer – how can the latter be monetized?

Chair: Clare Sarvary Fourrier, SVP, Clinical Operations – Europe, Precision for Medicine, Oncology and Rare Disease

Panellists:
1. Lars Gredsted, Associate Director Partnering and Strategy, AstraZeneca
2. Genghis Lloyd-Harris, Partner, Abingworth
3. Jutta Heix, International Advisor, Oslo Cancer Cluster
4. Garry Menzel, CEO of TCR2 Therapeutics
13.15 - 14.10

Panel: What's New in Neurodegenerative Disease, kindly sponsored by Cello Health

Neurodegenerative diseases are incurable and debilitating conditions that result in progressive degeneration of nerve cells, causing problems with movement or mental functioning.

Dementias are responsible for the greatest burden of neurodegenerative diseases, with Alzheimer’s representing approximately 60-70% of dementia cases.

This panel will gather together a group of thought leaders to discuss a range of issues facing researchers in this space, as well as hopes for future treatments and cures:

- What is the impact of neurodegenerative disease on global society?
- What are the greatest challenges currently facing R&D companies and Big Pharma in neurodegenerative research?
- Which companies are leading the way in research and are there any hero treatments on the horizon?
- What is the funding landscape for this space?
- What is the potential for using precision medicine in the treatment neurodegenerative diseases?
- Is there a link between the gut microbiome and neurodegenerative disease?

Chair: Joel Sandler, Associate Principal, Cello Health BioConsulting

Panellists:

1. Jenny Laird, VP, Search & Evaluation, Lilly
3. Ruth McKernan CBE, Senior Consultant, Dementia Discovery Fund
4. Simon Stott, Deputy Director of Research, The Cure Parkinson’s Trust
Panel: The Benefits and Challenges of Securing Chinese Investment

As the relationship between China and American remains rather strained, Chinese Biotech investors are turning their attention more and more to investing in European Biotech companies. Recent figures emerging show that China is investing nine times more into Europe than into North America.

Chinese investors hold great value in the European pharma and biotech market in both early and late stage, and are particularly interested in UK based companies, as a result of the government’s focus on life sciences within their industrial strategy.

However, dealing with Chinese investors is a very different proposition to dealing with those in Europe or America, with one of the main barriers to overcome being the lack of knowledge about how the market works and the products themselves.

Join us for a well-rounded discussion on the benefits and challenges of working with Chinese investors, and how as an R&D company considering this alternative source of funding, you can sufficiently prepare yourself to maximize the opportunity and build a positive long-term relationship.

Our expert panel will discuss all this and more, including:

- The importance of understanding the structure of the deal, e.g. is it a joint venture?
- Understand that many Chinese Investors will expect a fast return on their investment – does this suit your company?
- Do you have the time and resources available to ensure potential Chinese investors have the right level of knowledge about your product and organization?
- How can you safeguard your IP?
- What are the key regulatory matters to consider?

Chair: Kevin Holland, Minister - Counsellor Life Sciences, Health and Social Care, China DIT

Panellists:

1. Andy Richards CBE, Chairman, Congenica
2. Simon Haworth, CEO, Dynasty Bio
3. Nooman Haque, Managing Director, Life Sciences & Healthcare, Silicon Valley Bank
4. Garry Menzel, CEO, TCR2 Therapeutics
15.30 - 16.25

How to Value a Pre-Revenue Business, kindly sponsored by BDO

A company is ultimately only worth what someone is willing to pay, and as the leader of a pre-revenue business, it is important to go into any discussion with investors fully prepared and armed with the right information to ensure you receive a fair valuation that addresses the future prospects of the firm and that the ratio of capital gained verses equity surrendered is appropriate.

When valuing a pre-revenue business, traditional models of measurement don’t apply, as there are no profit or revenues to apply multipliers to.

Our panel of industry experts will consider all the factors that contribute to the valuation process, and highlight all you need to know including:

- The importance of a future facing approach
- Ensuring you present a credible company story with numbers anchored in
- Have a clear history of the funding you’ve received to date and an indication of the equity and other benefits you’ve offered
- Be aware of valuation trends in the industry, particularly of similar companies

Chair: Ian Oliver, Partner, BDO

Panellists:

1. Ed Higgs, Partner, BDO
2. Huw Jones, CEO, Chronos Therapeutics
3. Kaasim Mahmood, General Partner, Advent Life Sciences
16.30 - 17.15

Panel: Spotlight on Life Sciences Investment

This panel will feature a line-up of experts from the investment community who will share their insight on the current life sciences investment landscape, predictions for the next 12 months, advice for companies seeking investment and how to attract the right investor for your organisation.

After an introduction from each panellist, we’ll open up the floor for questions from the audience, on all matters relating to securing and maximising your investment.

Chair: Rebecca Todd, Investment Director, Longwall Venture Partners

Panel:

1. Geert-Jan Mulder, Managing Partner, Forbion
2. Oliver Sexton, Investment Director, UKI2S
3. Roger Franklin, Partner, Hadean Ventures
4. Elizabeth Klein, Founder and CEO, Klein-Edmonds Associates
Panel Abstracts and Speakers – Wednesday 1 May

09.30 - 10.05

Keynote: Healthy Ageing

Sarah Harper CBE, Professor of Gerontology, University of Oxford

Sarah is Professor of Gerontology at the University of Oxford, a Fellow at University College, and the Founding Director of the Oxford Institute of Population Ageing. Sarah served on the Prime Minister’s Council for Science and Technology, which advises the Prime Minister on the scientific evidence for strategic policies and frameworks. In 2017 she served as the Director of the Royal Institution of Great Britain. Sarah is a Director and Trustee of the UK Research Integrity Office and a member of the Board of Health Data Research UK. Sarah was appointed a CBE in 2018 for services to Demography.
Panel: What's New in Cell & Gene Therapy, kindly sponsored by Lonza

Nearly 50 years after the concept was first proposed, cell & gene therapy is now considered a promising treatment option for several human diseases. Development has been long, with many ups and downs, with serious adverse effects encountered in early clinical studies.

However, this fueled the research that led to safer and more efficient gene transfer vectors, and Cell & Gene therapy in various forms has gone on to produce clinical benefits in patients with blindness, neuromuscular disease, hemophilia, immunodeficiencies and cancer.

This expert panel at BioTrinity will discuss:
- The pioneering work that has led this space to where it is now
- What are the advances expected in the next few years?
- What are the practical challenges in getting these therapies to patients that need them, how can it become a mainstream option?
- How can Cell & Gene Therapy be monetised to make it commercially viable?

Chair:
Hartmut Tintrup, Director Business Development, Cell Therapy & Viral Therapy, Lonza

Panellists:
1. Ena Prosser, Partner, Fountain Healthcare Partners
2. Ryan Cawood, Founder and CEO, Oxford Genetics
3. Arthur Stril, VP Corporate Development, Cellectis
4. Joe Dupere, CEO, Rexgenero
11.05 - 12.05

Panel: What's New in Mental Health

Mental ill health is the single largest cause of disability in the UK, and it is estimated that almost a quarter of the country's population are affected by mental health issues each year. By 2030 it is predicted that mental health problems will be the main cause of global mortality and morbidity.

Many treatments for mental health conditions are no more advanced than they were 30 years ago, with mental health science still divided between psychiatry, clinical psychologists, nce, and data scientists.

It is now commonly thought that there is a clear need to move towards inter-disciplinary research to unify how mental illnesses are measured and ultimately treated, and this panel will address how researchers and clinicians who work within mental health science can work more collaboratively to improve patient diagnosis and treatment.

Our panel will also address:

- The risk of relying too heavily on drugs as the main treatment of mental ill-health – what are the alternatives?
- When to medicate, and the importance of reviewing treatments
- How are primary care settings encouraging more holistic patient centric approaches to mental health
- The role of digital healthcare in the treatment and management of mental ill-health

Chair: John Collins, Co-Founder, NeuroCreate

Panellists:

1. Ekaterina Malievskaia, Head of Research & Development and Co-Founder, COMPASS
2. Andy Blackwell, Group Chief Science and Strategy Officer, IESO Digital Health
3. Lennart Hergel, Partner, Ananda Ventures
4. Thalia Eley, Professor of Developmental Behavioural Genetics, King’s College London
12.30 - 13.00

**Keynote: Brexit – Where are We Now?**

James Tumbridge, Intellectual Property Litigation Partner, Venner Shipley

James Tumbridge, an intellectual property lawyer, who has been a ministerial advisor, and holds elected office with the City of London, will take us through what the UK relationship with the EU looks like, and what it might mean for the biotech world.
Panel: What's New in Autoimmune Disease, kindly sponsored by Lilly

More than 80 diseases occur as a result of the immune system attacking the body’s own organs, tissues, and cells, with common examples of autoimmune disease including rheumatoid arthritis, multiple sclerosis, psoriasis, lupus and inflammatory bowel disease.

Direct and indirect costs to the UK for just three autoimmune conditions alone, type-1 diabetes, rheumatoid arthritis and multiple sclerosis, currently adds up to more than £13 billion per year.

Our understanding of auto-immune disease has grown rapidly in the last 30 years or so, and of particular importance is the research revealing the fundamental part played by T cells to regulate immune responses.

This panel discussion will feature thought leaders and industry experts who will discuss the latest developments and challenges facing researchers in this space, including:

• What are the triggers that can cause auto-immune disease; can they help us find a cure?
• An update on the current research into the root causes of inflammation at a molecular level
• An insight into how boosting regulatory T cell activity can counter autoimmunity
• How to beat the ‘translational research time lag’
• How to improve funding for clinical trials

Chair: Su Metcalfe, Senior Research Associate, Cambridge Immunology Network

Panellists:
1. Hakan Goker, Senior Investment Director, M Ventures
2. Roly Foulkes, CSO, Immune Regulation
3. Heather Wasserman, Senior Director, Lilly
4. Anne Pesenacker, Arthritis Research UK Career Development Fellow, UCL Division of Infection and Immunity
Panel: Spotlight on Big Pharma

Big Pharma’s traditional business model depends on continuous innovation to drive value by generating greater patient benefits and addressing unmet need.

Join us for a fascinating debate on the latest trends, challenges and opportunities currently facing Big Pharma, including:

- What drives Big Pharma’s investment in external innovation, what are the key criteria they look for, and how do they cope with the impact of the negative return they often experience?
- Will Big Pharma continue the focus on outsourcing drug discovery and development and what will be the impact be on external Biotech companies & investors if & when this trend shifts?
- Is Big Pharma changing the strategic direction of their R&D therapeutic targets? What is predicted to be the next ‘big thing’?
- What are the predictions for future Big Pharma consolidation, including who, when and the impact this will have on the wider industry? What are the drivers for consolidation and does M&A activity truly add value?
- What pricing impact does the arrival of Biosimilars have on the market, especially in the US? Will the consequences be similar to the introduction of chemical generics, and what strategies are the industry employing to mitigate the financial effects?
- What are the potential impacts on the pharma industry should price controls on drug pricing come into force in the US?
- How can regulatory approval for new treatments be speeded up to create a longer period of IP exclusivity thus generating greater value to the industry?

Chair: John Harris, CEO, OBN

Panellists:

1. Graham Brazier, Vice President, Business Development, Bristol-Myers Squibb
2. Peter Hamley, Global Head, External Innovation, Drug Discovery Platforms, Sanofi
3. Johnston Erwin, Vice President, Corporate Business Development, Lilly
4. Florence Dal Degan, R&D Innovation Sourcing Director, Novo Nordisk
15.15 – 16.30

**Perfect Pitch**

Perfect Pitch returns for the fourth year and remains a highlight of the BioTrinity programme.

Perfect Pitch is a fast tempo and enjoyable session that sees 10 early-stage R&D Bi-oLaunchPad presenting companies give a three-minute presentation about their business, in front of both an eagle-eyed panel of industry judges and the BioTrinity delegate audience.

After the first round of presentations, judges will have a short time to discuss the content and delivery style of each presentation, before deciding on three presenters to progress through to the final round.

Finalists are all given feedback from the judges regarding the specific content they would like to hear about during their final presentation.

After the final round of presentations, the judges convene for the last time to decide who will be crowned ‘Perfect Pitch’ Champion 2019!

Previous winners have included:
- 2016 - Caroline Barelle, CEO of Elasmogen
- 2017 - Mike Karim, CEO of Oxford Endovascular
- 2018 - Jeremy Walsh, CEO of Cambridge Respiratory Innovations (CRiL)

**Presenting Companies**

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Presenter Name</th>
<th>Job Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avipero</td>
<td>Rehab Naylor</td>
<td>CSO</td>
</tr>
<tr>
<td>BRAINCURES Biotechnology</td>
<td>Jeanne-Francoise Williamson</td>
<td>Communications &amp; Marketing Manager</td>
</tr>
<tr>
<td>ILLUSTRATUM</td>
<td>David Trevor</td>
<td>CEO</td>
</tr>
<tr>
<td>Invizius</td>
<td>Richard Boyd</td>
<td>CEO</td>
</tr>
<tr>
<td>Neurocentrx Pharma</td>
<td>Carmel Reilly</td>
<td>CEO</td>
</tr>
<tr>
<td>PepGen</td>
<td>Caroline Godfrey</td>
<td>CEO</td>
</tr>
<tr>
<td>Synendos Therapeutics</td>
<td>Andrea Chicca</td>
<td>CEO</td>
</tr>
<tr>
<td>Talix Therapeutics</td>
<td>Jack Elands</td>
<td>CEO</td>
</tr>
<tr>
<td>Vaxinc</td>
<td>Salim Khakoo</td>
<td>Founder</td>
</tr>
</tbody>
</table>

**Chair:** Shawn Manning, Managing Director, Akesios Associates

**Judges:**

1. Sunil Shah, CEO, o2h Ventures
2. Maina Bhaman, Partner, Sofinnova Partners
3. Deborah Harland, Partner, SR One, GSK Medicines Research Centre
4. Kate Rowley, Investment Director, Biosciences Managers
5. Sue Charles, Managing Partner, Instinctif